Navigation Links
Osteotech Reports First Quarter 2009 Financial Results
Date:4/30/2009

e Company is currently waiting on a final decision from the French Regulatory Agency before lifting its temporary suspension.

  • Osteotech continued to strengthen its distribution network and during the first quarter the Company introduced a variety of new sales tools and educational programs focused on procedure specific applications for Plexur P and Grafton(R) DBM.

  • Shortly after the end of the first quarter, the Company completed its 6-month posterolateral fusion study of its proprietary MagniFuse(TM) Bone Graft in primates. The initial analysis of the data indicates that the quality and quantity of bone growth formed is superior to autograft and is competitive with the performance seen with growth factors (BMP) that were tested within the same challenging animal model. The study investigators will be submitting the results of this study for a podium talk and abstract to be presented in early 2010 and these results will be made available to support the market introduction of MagniFuse at the North American Spine Society (NASS) meeting in November 2009. This study supports the Company's strategy to introduce application-specific products with documented scientific and technical support.

Financial Results

Revenue for the three months ended March 31, 2009 was $23.9 million compared with $27.6 million for the three months ended March 31, 2008. The decline in first quarter 2009 revenue compared with 2008 was primarily driven by the expected reduction in revenue from client services and private label demineralized bone matrix, the anticipated decline in revenue stemming from the Company's international activities as a result of the temporary suspension of Bulgarian tissue and lower domestic unit sales volume.

Net loss for the first quarter ended March 3
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: ... technology-focused supplier of crop seeds in China ... its fiscal year 2014 ended September 30, 2014, before the ... Company will host a teleconference on January 8, 2015, at ... time to discuss the results. To participate in the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... NewLink Genetics Corporation today announced that additional data from ... HyperAcute® Pancreas cancer immunotherapy will be presented during a ... 2011 Gastrointestinal Cancers Symposium in San Francisco, California. A ... Title: Effect of the addition of algenpantucel-L immunotherapy to ...
... ROCKVILLE, Md., Jan. 20, 2011 OriGene Technologies, Inc. ... for developing an assay for every human protein through ... TrueMAB brand. Each TrueMAB antibody is specifically developed with ... for critical research and diagnostic needs requiring improved antibody ...
... Inc. (Nasdaq: RDEA ) today announced the ... 2,750,000 shares of its common stock, offered at a ... gross proceeds to Ardea from this offering are expected ... and other estimated offering expenses payable by Ardea.  BofA ...
Cached Biology Technology:NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 2NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 3NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 4OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies 2Ardea Biosciences Prices Public Offering of Common Stock 2Ardea Biosciences Prices Public Offering of Common Stock 3
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... A new University of Florida study shows ecologists may ... than 150 years. The study featured on the cover ... bone remains provide high-quality geographical data across an extensive time ... habitat for the conservation of threatened species. Charles ...
... 2012) Tufts University School of Engineering researchers have ... improvement in tissue imaging while simultaneously enabling photo ... delivery. The devices also lend themselves to a ... and biocompatible, these tiny mirror-like devices dissolve harmlessly ...
... NY Bread wheat ( Triticum aestivum ) is one ... of the calories consumed by people. Fully 35% of the ... survival. Now an international team of scientists, including a group ... comprehensive analysis of its full genome. The study ...
Cached Biology News:UF researcher tests powerful new tool to advance ecology, conservation 2UF researcher tests powerful new tool to advance ecology, conservation 3Implantable silk optics multi-task in the body 2Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: